These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38868321)

  • 1. Effect of JAK Inhibitors on the Risk of Death in Patients with Moderate to Severe COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kow CS; Ramachandram DS; Hasan SS
    Can J Hosp Pharm; 2024; 77(2):e3493. PubMed ID: 38868321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis.
    Wijaya I; Andhika R; Huang I; Purwiga A; Budiman KY; Bashari MH; Reniarti L; Roesli RMA
    Clin Epidemiol Glob Health; 2021; 11():100755. PubMed ID: 33969237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis.
    Zhang X; Shang L; Fan G; Gu X; Xu J; Wang Y; Huang L; Cao B
    Front Med (Lausanne); 2021; 8():800492. PubMed ID: 35155477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo.
    Pranić S; Pulumati A; Vuković D
    Syst Rev; 2024 Apr; 13(1):110. PubMed ID: 38641831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    Chen CY; Chen WC; Hsu CK; Chao CM; Lai CC
    Int Immunopharmacol; 2021 Oct; 99():108027. PubMed ID: 34343937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
    Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus Kinase Inhibitors and Adverse Events of Acne: A Systematic Review and Meta-Analysis.
    Martinez J; Manjaly C; Manjaly P; Ly S; Zhou G; Barbieri J; Mostaghimi A
    JAMA Dermatol; 2023 Dec; 159(12):1339-1345. PubMed ID: 37851459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis.
    Chen TL; Lee LL; Huang HK; Chen LY; Loh CH; Chi CC
    JAMA Dermatol; 2022 Nov; 158(11):1254-1261. PubMed ID: 36001310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis.
    Wei Q; Wang H; Zhao J; Luo Z; Wang C; Zhu C; Su N; Zhang S
    Front Pharmacol; 2023; 14():1237234. PubMed ID: 37614310
    [No Abstract]   [Full Text] [Related]  

  • 14. Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
    Liu M; Gao Y; Yuan Y; Yang K; Shen C; Wang J; Tian J
    JAMA Netw Open; 2023 Jun; 6(6):e2320351. PubMed ID: 37368402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials.
    Patoulias D; Doumas M; Papadopoulos C; Karagiannis A
    Clin Rheumatol; 2021 Nov; 40(11):4671-4674. PubMed ID: 34431004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis.
    Chen Q; Cui L; Hu Y; Chen Z; Gao Y; Shi Y
    Heliyon; 2023 Nov; 9(11):e22014. PubMed ID: 38034798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
    RECOVERY Collaborative Group
    Lancet; 2022 Jul; 400(10349):359-368. PubMed ID: 35908569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.
    Cai W; Tong R; Sun Y; Yao Y; Zhang J
    Front Pharmacol; 2024; 15():1387585. PubMed ID: 38725657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.
    Anglemyer A; Horvath HT; Bero L
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):MR000034. PubMed ID: 24782322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.